COMPUTEX-TAIPEI
8.2.2021 07:17:09 CET | Business Wire | Press release
Asia’s largest ICT show, COMPUTEX Taipei, is rolling out its first in Online-Merge-Offline (OMO) hybrid exhibition this year. COMPUTEX 2021 Hybrid combines the onsite exhibition with #COMPUTEXVirtual for an exceptionally vibrant, accessible, comprehensive show and customer experience. In addition, #InnoVEXVirtual will be held on a parallel track. Through the virtual experiences, COMPUTEX aims to help industry leaders and startup companies get the best exhibition performance results and greatest value.
COMPUTEX onsite Exhibition
The onsite COMPUTEX will take place at the Taipei Nangang Exhibition Center, Hall 1 & 2, from June 1-4. This year’s exhibition will revolve around seven major themes: 5G, AI & IoT, Edge Computing, High-Performance Computing (HPC), Cyber Security, Gaming, and Innovations & Startups. These themes showcase Taiwan’s historical and future supply chain dominance throughout the global ICT industry.
InnoVEX will debut at Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1) as a global startup stage to display inventions that stand to reshape the technology landscape worldwide.
#COMPUTEXVirtual Online Exhibition
#COMPUTEXVirtual will take place from May 31-June 30 online with #InnoVEXVirtual as a part of the online show. Together, the online exhibition will highlight the following four features:
- Tech Insights:
COMPUTEX Forum, InnoVEX Forum, keynote speeches from leading companies, live demonstrations and related webinars will be available via live-streaming. These resources will reveal the latest technology trends with insights into what’s next for the tech industry.
- Virtual Display:
Exhibitors will showcase their products at virtual booths via videos and images. Provided contact information allows exhibitors to seize every opportunity to generate leads without the hindrance of any time differences.
- Matchmaking and Networking:
Video conferencing, meeting requests and instant messaging make it possible to break down barriers across countries and establish the most effective, timely communication channels for exhibitors and buyers.
- Hyper-Personalized Recommendation:
#COMPUTEXVirtual will use AI technology to identify user behaviors and provide interesting marketing strategies to exhibitors. Hyper-Personalized Recommendations will help increase the matchmaking accuracy and shape brand perception.
COMPUTEX Hybrid Webinars to be held on March 3.
#COMPUTEXVirtual and #InnoVEXVirtual are now open for registration. To demonstrate how the online events leverage cutting-edge technologies to overcome time and geographical limitations, the event organizer, Taiwan External Trade Development Council, will hold international webinars on March 3.
- #COMPUTEXVirtual exhibitor registration:
https://events.taiwantrade.com/CVirtual01
- #InnoVEXVirtual exhibitor registration:
https://events.taiwantrade.com/IVirtual01
- COMPUTEX Hybrid Webinars:
https://events.taiwantrade.com/CVirtual02
For more update：
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website: https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210207005039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom